Drug Database
PR

prednisolone

✓ Approved

Takeda · NR3C1 · Small Molecule

What is prednisolone?

prednisolone is a small molecule developed by Takeda. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanyTakeda
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Takeda

Mechanism of Action

Molecular Targets

prednisolone acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

prednisolone is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved

Related Research Articles

PubMedInternational journal of pharmaceutics: X2026-09-20

Hydrodynamically decoupled nanoprecipitation (HDNP): A multi-stage strategy for supersaturation, controlled delayed nucleation, and stabilization of low LogP poorly-water soluble drugs.

Castillo-Henríquez Luis L, Mathieu Clélia C, Gahoual Rabah R, Pratama Dhanang Edy DE et al.

Poor aqueous solubility is a major drawback of modern drug candidates, affecting their biopharmaceutical performance. Solvent-antisolvent methods involving rapid mixing, such as Flash Nanoprecipitation and Sequential Nanoprecipitation, have advanced the field. However, these remain restricted to compounds with relatively high hydrophobicity (minimum LogP ≥4.5-6). To address this limitation, we introduce Hydrodynamically Decoupled Nanoprecipitation (HDNP). The approach enables decoupling supersaturation, nucleation, and stabilization by controlling the hydrodynamic environments. Dexamethasone (DEX, LogP: 1.83) was used as a model drug. A mechanistically and physics-informed framework was developed, integrating in-line dynamic light scattering for count rate evolution assessment, Computational Fluid Dynamics (CFD), and Design of Experiments for design space establishment. CFD revealed periodic shear stress, high turbulent dissipation rates, and local flow reversal during pulsatile flow under various Womersley numbers, providing favorable hydrodynamic conditions for controlled delayed nucleation. HDNP of DEX successfully produced mainly amorphous nanoparticles (DEX-NPs) stabilized with P407. DEX-NPs exhibited a hydrodynamic diameter of 241 nm, PdI of 0.246, loading efficiency of 77%, enhanced dissolution relative to the micronized drug, and physicochemical stability for at least two weeks. The approach was further evaluated using prednisolone (LogP: 1.62). These findings demonstrate the applicability of HDNP to the nanoprecipitation of the used corticosteroids and highlights its potential as a promising platform for other poorly water-soluble compounds with low LogP.

PMID 42763499
Read full article →
PubMedInternational journal of clinical oncology2026-09-19

Prognostic impact of diabetes or hypertension in smokers with CRPC receiving enzalutamide or abiraterone.

Fukagai Takashi T, Izumi Kouji K, Yamagishi Motoki M, Shima Takashi T et al.

Smoking and lifestyle‑related diseases increase the risk of cancer incidence and progression, but their impact on castration‑resistant prostate cancer (CRPC) remains unclear. This study examined whether diabetes mellitus (DM), hypertension (HT), and smoking habit (SH) affect the prognosis of CRPC patients treated with enzalutamide (ENZ) or abiraterone plus prednisolone (ABI). Using data from the ENABLE study for PCa, an investigator‑initiated, multicenter, randomized controlled trial, patients were retrospectively categorized into two groups based on SH. Subsequently, the impact of the absence or presence of either DM or HT and treatment arm (ENZ or ABI) on survival endpoints was investigated. A total of 178 patients were randomized and treated, of whom 161 had available SH information and were included in the analysis (84 SH- and 77 SH+). No significant differences in survival endpoints were observed between the SH- and SH+ groups. In the SH+ group, prostate cancer-specific survival (PCSS) was significantly worse in the with‑DM/HT group than in the no‑DM/HT group (p = 0.0215). Multivariate Cox analysis confirmed that the presence of DM or HT was an independent predictor of poor PCSS. Furthermore, a significant difference in PCSS between the no‑DM/HT and with‑DM/HT groups was observed in the ENZ arm (p = 0.0201), but not in the ABI arm. SH does not appear to influence the efficacy of ENZ or ABI therapy for CRPC; however, among SH+ patients, the presence of DM or HT was associated with poorer survival outcomes, particularly in those treated with ENZ.

PMID 42762423
Read full article →
PubMedEndocrine regulations2026-09-19

Prescription pattern of oral hydrocortisone by Indian healthcare professionals: An online questionnaire-based survey.

Valia Rama R, Jangir Ashish Kumar AK, Sahu Danendra D, Menon Jayakrishnan C JC et al.

Objective. Adrenal insufficiency is predominantly managed by glucocorticoids, from which hydrocortisone is most frequently prescribed. However, limited data are available on prescription patterns among Indian healthcare professionals (HCPs). This study assessed the prescription practices of hydrocortisone among Indian HCPs and evaluated their awareness of tapering protocols and necessity for modified-release formulations of hydrocortisone. Methods. This online questionnaire-based survey involved 300 HCPs across India who prescribe oral hydrocortisone for various endocrinological and non-endocrinological indications. Google Forms were used and survey was carried out over a period of two months. Only fully accomplished responses were included in the analysis and the response rate was calculated. Results. The survey response rate was 84.27%. Among HCPs, 94.7% prescribed oral hydrocortisone with 47.5% using it often and 28.9% very often. Prescription frequency varied from 29.9% (prescribed once weekly) to 25.7% (two or more times weekly). Awareness of approved indications was high (96.8%). Tapering protocols were widely practiced (95.4%) often or very often by 82.7% HCPs. Hydrocortisone was mainly prescribed for primary adrenal insufficiency (77.5%), secondary adrenal insufficiency (63.0%), and congenital adrenal hyperplasia (55.6%). Frequent adverse events included hyperglycemia (43.3%) and weight gain (43.0%). Most HCPs (89.8%) felt need for sustained-release hydrocortisone, particularly for primary adrenal insufficiency (81.7%). Alternatives of hydrocortisone mainly included prednisolone (65.8%), prednisone (37.3%), and dexamethasone (21.8%). Conclusion. Indian HCPs frequently prescribe oral hydrocortisone and are well-versed in tapering protocols. However, frequent adverse events and unmet needs emphasize strong demand for modified-release formulations, particularly for management of adrenal insufficiency.

PMID 42762503
Read full article →
PubMedCase reports in rheumatology2026-09-18

Dose-Escalated Upadacitinib for Refractory Myositis in Anti-Jo-1-Positive Antisynthetase Syndrome: A Case Report.

Kukida Yuji Y, Inoue Hironori H

Anti-Jo-1-positive antisynthetase syndrome (ASS) can follow a relapsing course during glucocorticoid tapering, and evidence for refractory myositis remains limited. We report a 33-year-old woman with anti-Jo-1-positive ASS with a dermatomyositis phenotype and recurrent myositis despite multiple immunosuppressants, biologics, and Janus kinase (JAK) inhibitors. Upadacitinib was increased from 15 to 30 mg/day during a flare, together with intravenous immunoglobulin and temporary prednisolone escalation. During follow-up, upadacitinib was withdrawn twice for fertility treatment; both withdrawals were followed by disease flares, and disease control was restored after reintroduction. Prednisolone was ultimately discontinued. This repeated withdrawal-rechallenge pattern suggests that dose-escalated upadacitinib may have contributed to sustained disease control.

PMID 42756780
Read full article →
PubMedRheumatology (Oxford, England)2026-09-18

Reduced severe infection risk with avacopan in ANCA-associated vasculitis: a multicentre REVEAL cohort with time-varying exposure modelling.

Yoshida Tsuneyasu T, Hiwa Ryosuke R, Shoji Mikihito M, Manabe Atsushi A et al.

To evaluate the association between avacopan (AVA) use and recurrent relapse and severe infection in patients with ANCA-associated vasculitis, with particular attention to time-varying treatment and glucocorticoid exposure. In this multicentre retrospective cohort study, AVA use was modelled as a time-varying exposure. Stabilized inverse probability of treatment weighting was used to adjust for baseline differences. Recurrent relapse and severe infection, defined as an infection requiring hospitalisation, were analysed using time-dependent Cox proportional hazards models based on the Andersen-Gill formulation. Exploratory models additionally incorporated time-varying and cumulative prednisolone exposure. A total of 387 patients were included, of whom 52 received AVA and 335 did not. AVA exposure was associated with a lower estimated risk of severe infection (adjusted HR 0.22, 95% CI 0.07-0.68; P = 0.008), whereas no statistically significant difference in recurrent relapse risk was observed. AVA use was also associated with lower prednisolone exposure over time. This association with severe infection remained directionally consistent in glucocorticoid-adjusted models, although its magnitude varied depending on model specification. In this multicentre real-world cohort, AVA exposure was associated with a lower estimated risk of severe infection and reduced glucocorticoid exposure, whereas no statistically significant reduction in recurrent relapse risk was observed. These findings suggest that an AVA-containing treatment strategy may be associated with improved infection-related outcomes in routine practice, although the observational design precludes causal inference.

PMID 42757695
Read full article →
PubMedNigerian medical journal : journal of the Nigeria Medical Association2026-09-18

Neuroschistosomiasis Mimicking Spinal Tuberculosis: A Case Report.

Abubakar Muhammadu Sani MS, Muazu Jabiru J, Yusuf Abdulwahab Elladan AE, Abubakar Nasir Bakiyawa NB et al.

Schistosomiasis is a chronic parasitic disease acquired through freshwater exposure, in which cercariae penetrate the skin and mature into adult worms. Disease manifestations largely result from granulomatous inflammation and fibrosis surrounding retained eggs. A 65-year-old widow presented with six months of lower back pain, weight loss, paraplegia (power 1/5), sphincter dysfunction, a T12 sensory level, and T9-T10 gibbus. She had received empirical antitubercular therapy for two months without improvement. Thoracolumbar MRI demonstrated vertebral and disc collapse at T10-T11 and L1-L2, with adjacent paravertebral abscesses and cord compression. Surgical biopsies revealed numerous calcified Schistosoma haematobium eggs with terminal spines, surrounded by granulomas containing epithelioid histiocytes, foreign-body giant cells, lymphocytes, and eosinophils. She received weekly praziquantel (1,200 mg) and tapered prednisolone. Motor power improved to 2/5, although urinary and faecal incontinence persisted. Neuroschistosomiasis should be considered in endemic regions, particularly when presumed spinal tuberculosis fails to respond to treatment. Definitive diagnosis requires careful clinicoradiological and histopathological evaluation.

PMID 42756785
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about prednisolone